In today’s briefing:
- Japan Strategy Weekly | Thanksgiving Rally
- APAC Healthcare Weekly (November 30) – Kelun Bio, ImmuneOnco, Otsuka, Eisai, Alteogen, SK Biopharma
Japan Strategy Weekly | Thanksgiving Rally
- Japanese equities rebounded strongly this week, with the Nikkei 225 up 3.3% and TOPIX up 2.4%, nearly reversing the prior week’s sharp losses.
- This week’s top performer was Toppan Printing due to strong interest in its “Double View Film” for solar panels and a new data-driven customer-experience service, highlighting innovation and growth potential.
- A quieter week for Activists. Dalton increased its Anicom stake to 9.5%, signalling confidence in the pet insurer’s stable growth and potential capital returns.
APAC Healthcare Weekly (November 30) – Kelun Bio, ImmuneOnco, Otsuka, Eisai, Alteogen, SK Biopharma
- Sichuan Kelun-Biotech announces Phase 3 trial success for ADC-Keytruda combination therapy in first-line lung cancer. ImmuneOnco received Phase 3 trial approval for IMM0306 lenalidomide combination for follicular lymphoma in China.
- Otsuka received FDA accelerated approval of Voyxact for immunoglobulin A nephropathy. Eisai has completed FDA submission of Leqembi Iqlik subcutaneous autoinjector as a weekly starting dose for early Alzheimer’s disease.
- Alteogen secures $15M milestone payment from Merck as Keytruda subcutaneous formulation gets EU approval. SK Biopharmaceuticals in-licenses second radiopharmaceutical candidate, which has potential to target clear cell renal cell carcinoma.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
